Varsha Raghavan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Varsha Raghavan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Dan Rudolph Littman
Department of Cell Biology, New York University School of Medicine, New York, NY, USA.
4 shared publications - Aaron Watters
Flatiron Institute Center for Computational Biology, Simons Foundation
1 shared publication - Adrian Tett
Centre for Integrative Biology, University of Trento, Trento, Italy
1 shared publication - Andreza M.S. Gama
Laboratório de Inflamação e Imunidade, Departamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro – Rio de Janeiro, Brasil
1 shared publication - Bahtiyar Yilmaz
Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Maurice Müller Laboratories, Department for Biomedical Research, University of Bern, 3008 Bern, Switzerland; Bern Center for Precision Medicine (BCPM), University of Bern, 3008 Bern, Switzerland
1 shared publication - Cara Magnabosco
ETH Zurich
1 shared publication
Latest Publications
- Open Access
Disease tolerant mice shelter a pathogenic intestinal microbiota able to trigger lethal disease in low tolerant hosts
Disease tolerance is a defensive strategy that limits tissue damage during infection. Macrophage migration inhibitory factor (MIF)-deficient mice ( Mif -/- ) are protected in different models of infection and intestinal inflammation due to unclear disease tolerance mechanisms, whereas low disease-tolerant Il10 -/- mice develop microbiota-dependent spontaneous gut inflammation. Here, we examined whether IL-10 is required for the phenotype seen in Mif -/- mice and, conversely, the contribution of MIF during IL-10 deficiency. While breeding for double-deficient Mif -/- Il10 -/- mice, we unexpectedly observed that Il10 -/- individuals died within days after co-housing with Mif -/- mice. We found that healthy Mif -/- hosts endure a highly diverse, unique and dysbiotic-like microbiota composition, including antibiotic-resistant Enterobacteriaceae species, which were sufficient to cause acute and lethal Th1-driven colitis in Il10 -/- recipients. The disease was characterized by increased frequencies of IFNγ + cells and neutrophils within colonic lamina propria. Mif -/- Il10 -/- mice died prematurely, and survivors developed communicable disease, - indicating that lack of IL-10 is a dominant trait. These findings suggest that tolerant individuals harbor a gut microbiota enriched in pathogens/pathobionts, which can trigger disease in susceptible hosts.
Open AccessDisease tolerant mice shelter a pathogenic intestinal microbiota able to trigger lethal disease in low tolerant hosts
Disease tolerance is a defensive strategy that limits tissue damage during infection. Macrophage migration inhibitory factor (MIF)-deficient mice ( Mif -/- ) are protected in different models of infection and intestinal inflammation due to unclear disease tolerance mechanisms, whereas low disease-tolerant Il10 -/- mice develop microbiota-dependent spontaneous gut inflammation. Here, we examined whether IL-10 is required for the phenotype seen in Mif -/- mice and, conversely, the contribution of MIF during IL-10 deficiency. While breeding for double-deficient Mif -/- Il10 -/- mice, we unexpectedly observed that Il10 -/- individuals died within days after co-housing with Mif -/- mice. We found that healthy Mif -/- hosts endure a highly diverse, unique and dysbiotic-like microbiota composition, including antibiotic-resistant Enterobacteriaceae species, which were sufficient to cause acute and lethal Th1-driven colitis in Il10 -/- recipients. The disease was characterized by increased frequencies of IFNγ + cells and neutrophils within colonic lamina propria. Mif -/- Il10 -/- mice died prematurely, and survivors developed communicable disease, - indicating that lack of IL-10 is a dominant trait. These findings suggest that tolerant individuals harbor a gut microbiota enriched in pathogens/pathobionts, which can trigger disease in susceptible hosts.
- Open Access
- 17 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD, formerly known as NAFLD) is a major driver of cirrhosis and liver-related mortality. However, therapeutic options for MASLD, including prevention of liver steatosis, are limited. We previously described that vasoactive intestinal peptide–producing neurons (VIP-neurons) regulate the efficiency of intestinal dietary fat absorption and IL-22 production by type 3 innate lymphoid cells (ILC3) in the intestine. Given the described hepatoprotective role of IL-22, we hypothesize that modulation of this neuroimmune circuit could potentially be an innovative approach for the control of liver steatosis. Methods: We used a model of diet-induced MASLD by exposing mice to a high-fat diet (HFD) for 16 weeks, when the development of liver steatosis was first observed in our animals. We characterized IL-22 production by intestinal ILC3 at this dietary endpoint. We then evaluated whether communication between VIP-neurons and ILC3 affected IL-22 production and MASLD development by exposing mice with a conditional genetic deletion of Vipr2 in ILC3 (Rorc(t) Cre Vipr2 fl/fl ) to the HFD. We also performed intermittent global inhibition of VIP-neurons using a chemogenetic inhibitory approach (Vip Ires-Cre hM4Di LSL ) in HFD-fed mice. Results: Production of IL-22 by intestinal ILC3 is reduced in steatotic mice that were exposed to an HFD for 16 weeks. Targeted deletion of VIP receptor 2 in ILC3 resulted in higher production of IL-22 in ILC3 and was associated with a significant reduction in liver steatosis in mice under HFD. Global inhibition of VIP-producing neurons also resulted in a significant reduction in liver steatosis. Conclusions: Modulating VIPergic neuroimmune signaling can ameliorate the development of hepatic steatosis induced by a surplus of fat ingestion in the diet. This neuroimmune pathway should be further investigated as a potential therapeutic avenue in MASLD.
- 17 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Open AccessModulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD, formerly known as NAFLD) is a major driver of cirrhosis and liver-related mortality. However, therapeutic options for MASLD, including prevention of liver steatosis, are limited. We previously described that vasoactive intestinal peptide–producing neurons (VIP-neurons) regulate the efficiency of intestinal dietary fat absorption and IL-22 production by type 3 innate lymphoid cells (ILC3) in the intestine. Given the described hepatoprotective role of IL-22, we hypothesize that modulation of this neuroimmune circuit could potentially be an innovative approach for the control of liver steatosis. Methods: We used a model of diet-induced MASLD by exposing mice to a high-fat diet (HFD) for 16 weeks, when the development of liver steatosis was first observed in our animals. We characterized IL-22 production by intestinal ILC3 at this dietary endpoint. We then evaluated whether communication between VIP-neurons and ILC3 affected IL-22 production and MASLD development by exposing mice with a conditional genetic deletion of Vipr2 in ILC3 (Rorc(t) Cre Vipr2 fl/fl ) to the HFD. We also performed intermittent global inhibition of VIP-neurons using a chemogenetic inhibitory approach (Vip Ires-Cre hM4Di LSL ) in HFD-fed mice. Results: Production of IL-22 by intestinal ILC3 is reduced in steatotic mice that were exposed to an HFD for 16 weeks. Targeted deletion of VIP receptor 2 in ILC3 resulted in higher production of IL-22 in ILC3 and was associated with a significant reduction in liver steatosis in mice under HFD. Global inhibition of VIP-producing neurons also resulted in a significant reduction in liver steatosis. Conclusions: Modulating VIPergic neuroimmune signaling can ameliorate the development of hepatic steatosis induced by a surplus of fat ingestion in the diet. This neuroimmune pathway should be further investigated as a potential therapeutic avenue in MASLD.
- Open Access
- 2 September 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (11)
Arkadia-SKI/SnoN signaling differentially regulates TGF-β–induced iTreg and Th17 cell differentiation
TGF-β signaling is fundamental for both Th17 and regulatory T (Treg) cell differentiation. However, these cells differ in requirements for downstream signaling components, such as SMAD effectors. To further characterize mechanisms that distinguish TGF-β signaling requirements for Th17 and Treg cell differentiation, we investigated the role of Arkadia (RNF111), an E3 ubiquitin ligase that mediates TGF-β signaling during development. Inactivation of Arkadia in CD4+ T cells resulted in impaired Treg cell differentiation in vitro and loss of RORγt+FOXP3+ iTreg cells in the intestinal lamina propria, which increased susceptibility to microbiota-induced mucosal inflammation. In contrast, Arkadia was dispensable for Th17 cell responses. Furthermore, genetic ablation of two Arkadia substrates, the transcriptional corepressors SKI and SnoN, rescued Arkadia-deficient iTreg cell differentiation both in vitro and in vivo. These results reveal distinct TGF-β signaling modules governing Th17 and iTreg cell differentiation programs that could be targeted to selectively modulate T cell functions.
- 2 September 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (11)
Open AccessArkadia-SKI/SnoN signaling differentially regulates TGF-β–induced iTreg and Th17 cell differentiation
TGF-β signaling is fundamental for both Th17 and regulatory T (Treg) cell differentiation. However, these cells differ in requirements for downstream signaling components, such as SMAD effectors. To further characterize mechanisms that distinguish TGF-β signaling requirements for Th17 and Treg cell differentiation, we investigated the role of Arkadia (RNF111), an E3 ubiquitin ligase that mediates TGF-β signaling during development. Inactivation of Arkadia in CD4+ T cells resulted in impaired Treg cell differentiation in vitro and loss of RORγt+FOXP3+ iTreg cells in the intestinal lamina propria, which increased susceptibility to microbiota-induced mucosal inflammation. In contrast, Arkadia was dispensable for Th17 cell responses. Furthermore, genetic ablation of two Arkadia substrates, the transcriptional corepressors SKI and SnoN, rescued Arkadia-deficient iTreg cell differentiation both in vitro and in vivo. These results reveal distinct TGF-β signaling modules governing Th17 and iTreg cell differentiation programs that could be targeted to selectively modulate T cell functions.
- Open Access
Distinct polysaccharide growth profiles of human intestinal Prevotella copri isolates
Summary: The gut-dwelling Prevotella copri , the most prevalent Prevotella species in human gut, have been associated with diet as well as disease, but our understanding of their diversity and functional roles remains rudimentary, as studies have been limited to 16S and metagenomic surveys and experiments using a single type strain. Here, we describe the genomic diversity of 83 P. copri isolates from 11 donors. We demonstrate that genomically distinct isolates, which can be categorized into different P. copri complex clades, utilize defined sets of plant polysaccharides that can be predicted in part from their genomes and from metagenomic data. This study thus reveals both genomic and functional differences in polysaccharide utilization between several novel human intestinal P. copri strains.
Open AccessDistinct polysaccharide growth profiles of human intestinal Prevotella copri isolates
Summary: The gut-dwelling Prevotella copri , the most prevalent Prevotella species in human gut, have been associated with diet as well as disease, but our understanding of their diversity and functional roles remains rudimentary, as studies have been limited to 16S and metagenomic surveys and experiments using a single type strain. Here, we describe the genomic diversity of 83 P. copri isolates from 11 donors. We demonstrate that genomically distinct isolates, which can be categorized into different P. copri complex clades, utilize defined sets of plant polysaccharides that can be predicted in part from their genomes and from metagenomic data. This study thus reveals both genomic and functional differences in polysaccharide utilization between several novel human intestinal P. copri strains.